Microbiome-orchestrated cross-organ immunity in autoimmunity: from metabolites to therapeutic targets
Frontiers in Immunology · 2026
DOI: 10.3389/fimmu.2026.1761834 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, 2026. Verfasst von Xianlin Rao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Disease, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Autoimmunity, Gastrointestinal Microbiome, Autoimmune Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Autoimmune diseases are systemic disorders in which barrier-site immune activation, especially in the gut, can reshape inflammatory programs in distant organs. This review advances a metabolite-centered, cross-organ framework for understanding how gut microbial ecology influences autoimmunity beyond individual gut-organ axes. We synthesize evidence that short-chain fatty acids, bile acid derivatives, tryptophan catabolites, polyamines and related microbial products act as mobile biochemical checkpoints linking intestinal barrier integrity, pattern-recognition signaling, immune-cell metabolism and tissue-specific inflammation in joints, kidneys, skin, lungs and the central nervous system. Across these axes, shared mechanisms include barrier failure, altered microbial metabolite pools, dysregulated MAMP sensing, trafficking or systemic conditioning of lymphoid and myeloid cells, and local stromal imprinting in target organs. We also discuss sex-dependent microbiome-immune interactions, including the microgenderome concept, as a framework for explaining why microbiome composition, hormone metabolism and immune responses may shape autoimmune risk and treatment response differently in females and males. Finally, we evaluate multi-omics, single-cell and spatial profiling, organ-on-chip platforms and causal computational tools, and we outline translational strategies ranging from diet, probiotics, fecal microbiota transplantation and engineered consortia to pharmacologic targeting of metabolite receptors. By treating microbial metabolites as actionable cross-organ immune checkpoints, this review highlights opportunities and limitations for biomarker-guided, metabolite-focused precision therapy in autoimmunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Infectious Disease, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China.
- Department of Pharmacy, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China.
- Department of Pharmacy, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China.
- Department of Pharmacy, Women's Hospital School of Medicine, Zhejiang University, Hangzhou, China.
Zitieren
APA
Rao, X., Zou, L., Cai, X., Yao, Y., & Zhong, L. (2026). Microbiome-orchestrated cross-organ immunity in autoimmunity: from metabolites to therapeutic targets. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1761834
Vancouver
Rao X, Zou L, Cai X, Yao Y, Zhong L. Microbiome-orchestrated cross-organ immunity in autoimmunity: from metabolites to therapeutic targets. Frontiers in Immunology. 2026. doi:10.3389/fimmu.2026.1761834
BibTeX
@article{Rao2026,
author = {Rao, Xianlin and Zou, Li and Cai, Xiaoyu and Yao, Yao and Zhong, Lingling},
title = {Microbiome-orchestrated cross-organ immunity in autoimmunity: from metabolites to therapeutic targets},
journal = {Frontiers in Immunology},
year = {2026},
doi = {10.3389/fimmu.2026.1761834}
}
EUVIMED